2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Great Hall BC
Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Genomics, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

249 Safety, tolerability, and efficacy of mesutoclax (ICP-248) combined with azacitidine in patients with treatment-Naïve Myelodysplastic Syndromes (MDS)

Huafeng Wang, MD, Amer M. Zeidan, MD2, Xiaobing Huang, MD3, Sujun Gao, MD4, Li Wang, MD5, Suning Chen, MD, PhD6, Ling Jiang7, Aijun Liao, MD, PhD8, Xudong Wei, MD, PhD9, Zhichao Chen, MD10, Xingli Zhao, MD11, Fei Li, MD12, Qian Jiang Jr, MD13, Xiaoyu Zhu, MD14, Jianyu Weng, MD, PhD15, Xiaoxi Zeng16, Haowen Xu17, Chen Luo18, Weige Wang, MD, PhD19, Renbin Zhao, PhD20, Jie Jin, MD21
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Yale School of Medicine, Yale University, New haven,CT, United States
3 Sichuan Provincial People’s Hospital, Chengdu, China
4 The First Hospital of Jilin University, Changchun, China
5 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
6 The First Affiliated Hospital of Soochow University, Suzhou, China
7 Nanfang Hospital of Southern Medical University, Guangzhou, China
8 Shengjing Hospital of China Medical University, Shenyang, China
9 Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
10 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 Tianjin People's Hospita, Tianjin, China
12 The First Affiliated Hospital of Nanchang University, Nanchang, China
13 Peking University People's Hospital, Beijing, China
14 Anhui Provincial Hospital, Hefei, China
15 Guangdong Provincial People's Hospital, Guangzhou, China
16 InnoCare Pharma Limited, Beijing, Beijing, China
17 InnoCare Pharma Limited, Beijing, Beijing, China
18 InnoCare Pharma Limited, Beijing, Beijing, China
19 InnoCare Pharma Limited, Beijing, Beijing, China
20 InnoCare Pharma Limited, Beijing, Beijing, China
21 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background:
Venetoclax(Ven) combined with hypomethylating agents is approved for newly diagnosed acute myeloid leukemia in unfit patients but has failed to demonstrate survival benefits in treatment-naïve (TN) higher-risk myelodysplastic syndromes (HR-MDS) in the randomized phase 3 trial VERONA. Mesutoclax (ICP-248) is a novel, potent, and highly selective BCL-2 inhibitor. Compared to Ven, it exhibits a favorable pharmacokinetic profile without major active circulating metabolites and has demonstrated encouraging preliminary clinical activity. Here, we report the safety, tolerability, and efficacy of mesutoclax in combination with azacitidine (AZA) in patients with TN MDS from an ongoing phase 1 study (NCT06656494).

 

Methods:
Patients with TN HR-MDS (Revised International Prognostic Scoring System [IPSS-R] >3 and bone marrow blasts ≥5%) were eligible. Mesutoclax (100, 125, or 150 mg) was administered orally once daily on days 1–14 in combination with AZA (75 mg/m²/day for 7 days: days 1–7 or days 1–5 and 8–9) per 28-day cycle. Two recommended doses for expansion (RDEs: 100 mg and 125 mg QD) are currently being evaluated in TN MDS. Treatment responses were assessed using both International Working Group (IWG) 2006 and IWG 2023 response criteria.

 

Results:
As of July 13, 2026, 40 patients with TN HR-MDS were enrolled (100 mg cohort, n=16; 125 mg cohort, n=24). The median age was 66 years (range: 39–79), and 67.5% (27/40) were males. Baseline IPSS-R risk categories were intermediate in 20.0% (8/40), high in 30.0% (12/40), and very high in 50.0% (20/40). At a median follow-up of 2.9 months, patients received a median of 2.0 treatment cycles.

Among 36 efficacy-evaluable patients, the composite CR (CRc) rate per IWG 2023 criteria was 80.6% (29/36), including CR in 38.9% (14/36) and CR with limited recovery (CRL) in 41.7% (15/36). In the 125 mg cohort (n=20 evaluable), the IWG 2023 CRc rate reached 85.0% (17/20; CR, 40.0% [8/20]; CRL, 45.0% [9/20]). According to IWG 2006 criteria, the overall response rate (ORR) was 83.3% (30/36).

No dose-limiting toxicities (DLTs) or tumor lysis syndrome (TLS) events were observed, and no treatment-emergent adverse events (TEAEs) led to dose discontinuation. Serious adverse events (SAEs) occurred in 25.0% (10/40) of patients, and grade ≥3 TEAEs occurred in 85.0% (34/40). The most common grade ≥3 TEAEs were decreased neutrophil count (62.5%), decreased platelet count (42.5%), anemia (17.5%), pneumonia (17.5%), and decreased lymphocyte count (12.5%).

 

Conclusion:
Mesutoclax plus azacitidine demonstrates a favorable safety profile and robust blast clearance with most patients achieving meaningful count recovery (IWG 2023 CRc up to 85.0%) in patients with TN HR-MDS. These encouraging data support further evaluation of mesutoclax in HR-MDS, additional patients will be studied, including from the USA and Australia.

Huafeng Wang, MD: No relevant conflicts of interest to declare.